Skip to main content
Journal cover image

Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients.

Publication ,  Journal Article
Chouinard, ML; Martin, LL; Coffman, T; Hamilton, BH; Linberg, LF; Pamidi, A; Simke, JP; Rakhit, A
Published in: Clin Pharmacol Ther
December 1992

The effects of a 48-hour 0.5 mg/kg/hr infusion of the thromboxane synthase inhibitor pirmagrel were studied in 10 renal allograft recipients with cyclosporine nephrotoxicity. Plasma concentrations reached a mean steady-state plasma level of 1798 +/- 481 ng/ml. Biphasic, rapid elimination of pirmagrel was observed with a distribution half-life of 6.7 minutes and a terminal half-life of 73 minutes. Plasma clearance and the volume of distribution of the drug were 300 +/- 87 ml/hr/kg and 497 +/- 232 ml/kg, respectively. The pharmacodynamic effects of pirmagrel were marked by a mean 96% suppression of serum thromboxane B2 (TXB2), which coincided with a suppression of urinary excretion of TXB2, 2,3-dinor-TXB2, and 11-dehydro-TXB2 of 85% +/- 8%, 91% +/- 5%, and 89% +/- 9%, respectively. Urinary excretion of all thromboxane metabolites measured at the end of 1 week after termination of infusion was returned to the baseline. In conclusion, pirmagrel caused effective and sustained suppression of all thromboxane derived metabolites in plasma and urine during continuous infusion in kidney transplant patients receiving cyclosporine.

Duke Scholars

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

December 1992

Volume

52

Issue

6

Start / End Page

597 / 604

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Thromboxane-A Synthase
  • Thromboxane B2
  • Radioimmunoassay
  • Pyridines
  • Pharmacology & Pharmacy
  • Kidney Transplantation
  • Infusions, Intravenous
  • Imidazoles
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chouinard, M. L., Martin, L. L., Coffman, T., Hamilton, B. H., Linberg, L. F., Pamidi, A., … Rakhit, A. (1992). Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. Clin Pharmacol Ther, 52(6), 597–604. https://doi.org/10.1038/clpt.1992.197
Chouinard, M. L., L. L. Martin, T. Coffman, B. H. Hamilton, L. F. Linberg, A. Pamidi, J. P. Simke, and A. Rakhit. “Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients.Clin Pharmacol Ther 52, no. 6 (December 1992): 597–604. https://doi.org/10.1038/clpt.1992.197.
Chouinard ML, Martin LL, Coffman T, Hamilton BH, Linberg LF, Pamidi A, et al. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. Clin Pharmacol Ther. 1992 Dec;52(6):597–604.
Chouinard, M. L., et al. “Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients.Clin Pharmacol Ther, vol. 52, no. 6, Dec. 1992, pp. 597–604. Pubmed, doi:10.1038/clpt.1992.197.
Chouinard ML, Martin LL, Coffman T, Hamilton BH, Linberg LF, Pamidi A, Simke JP, Rakhit A. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. Clin Pharmacol Ther. 1992 Dec;52(6):597–604.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

December 1992

Volume

52

Issue

6

Start / End Page

597 / 604

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Thromboxane-A Synthase
  • Thromboxane B2
  • Radioimmunoassay
  • Pyridines
  • Pharmacology & Pharmacy
  • Kidney Transplantation
  • Infusions, Intravenous
  • Imidazoles
  • Humans